These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 6722935)

  • 1. Identification of the specific sites of interaction between intercalating drugs and DNA.
    Robbie M; Wilkins RJ
    Chem Biol Interact; 1984 Apr; 49(1-2):189-207. PubMed ID: 6722935
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human mismatch repair and G*T mismatch binding by hMutSalpha in vitro is inhibited by adriamycin, actinomycin D, and nogalamycin.
    Larson ED; Drummond JT
    J Biol Chem; 2001 Mar; 276(13):9775-83. PubMed ID: 11134041
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The relationship between frameshift mutagenicity and DNA-binding affinity in a series of acridine-substituted derivatives of the experimental antitumour drug 4'-(9-acridinylamino)methanesulphonanilide (AMSA).
    Ferguson LR; Baguley BC
    Mutat Res; 1981 Jun; 82(1):31-9. PubMed ID: 7022171
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antihelicase action of DNA-binding anticancer agents: relationship to guanosine-cytidine intercalator binding.
    Bachur NR; Johnson R; Yu F; Hickey R; Applegren N; Malkas L
    Mol Pharmacol; 1993 Nov; 44(5):1064-9. PubMed ID: 8246909
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intercalating drugs: DNA binding and molecular pharmacology.
    Wilson WD; Jones RL
    Adv Pharmacol Chemother; 1981; 18():177-222. PubMed ID: 6172965
    [No Abstract]   [Full Text] [Related]  

  • 6. DNA-binding abilities of bisguanylhydrazones of anthracene-9,10-dicarboxaldehyde.
    Foye WO; Karnik PS; Sengupta SK
    Anticancer Drug Des; 1986 Apr; 1(2):65-71. PubMed ID: 2453195
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The molecular basis for the action of some DNA-binding drugs.
    Neidle S
    Prog Med Chem; 1979; 16():151-221. PubMed ID: 95595
    [No Abstract]   [Full Text] [Related]  

  • 8. Alteration of chromatin structure induced by the binding of adriamycin, daunorubicin and ethidium bromide.
    Grimmond HE; Beerman T
    Biochem Pharmacol; 1982 Nov; 31(21):3379-86. PubMed ID: 7150361
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interaction of intercalating and non-intercalating agents with DNA: use of hydroxyapatite chromatography and S1 nuclease.
    Alvi NK; Rizvi RY; Hadi SM
    Chem Biol Interact; 1985; 53(1-2):219-31. PubMed ID: 2986859
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Covalent attachment of ethidium to DNA results in enhanced topoisomerase II-mediated DNA cleavage.
    Marx G; Zhou H; Graves DE; Osheroff N
    Biochemistry; 1997 Dec; 36(50):15884-91. PubMed ID: 9398321
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nonintercalative DNA-binding antitumour compounds.
    Baguley BC
    Mol Cell Biochem; 1982 Apr; 43(3):167-81. PubMed ID: 6283334
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Investigation of DNA dynamics and drug-DNA interaction by steady state fluorescence anisotropy.
    Genest D; Mirau PA; Kearns DR
    Nucleic Acids Res; 1985 Apr; 13(7):2603-15. PubMed ID: 4000964
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of AT and GC sequence specific minor groove-binding agents on restriction endonuclease activity.
    Forrow SM; Lee M; Souhami RL; Hartley JA
    Chem Biol Interact; 1995 May; 96(2):125-42. PubMed ID: 7728903
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Binding of actinomycin D to the T(G)nT motif of double-stranded DNA: determination of the guanine requirement in nonclassical, non-GpC binding sites.
    Bailey SA; Graves DE; Rill R
    Biochemistry; 1994 Sep; 33(38):11493-500. PubMed ID: 7918362
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug-DNA sequence-dependent interactions analysed by electric linear dichroism.
    Bailly C; Hénichart JP; Colson P; Houssier C
    J Mol Recognit; 1992 Dec; 5(4):155-71. PubMed ID: 1339484
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polymerase-chain reaction as a tool for investigations on sequence-selectivity of DNA-drugs interactions.
    Passadore M; Feriotto G; Bianchi N; Aguiari G; Mischiati C; Piva R; Gambari R
    J Biochem Biophys Methods; 1994 Dec; 29(3-4):307-19. PubMed ID: 7699207
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, synthesis, DNA binding, and biological activity of a series of DNA minor-groove-binding intercalating drugs.
    Bailly C; Pommery N; Houssin R; Henichart JP
    J Pharm Sci; 1989 Nov; 78(11):910-7. PubMed ID: 2621573
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Quenching of ethidium-DNA fluorescence by novel acridines with antitumor activities].
    Kimura M
    Yakugaku Zasshi; 1992 Dec; 112(12):914-8. PubMed ID: 1294716
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting DNA through-covalent interactions of reversible binding drugs.
    Graves DE
    Methods Enzymol; 2001; 340():377-95. PubMed ID: 11494860
    [No Abstract]   [Full Text] [Related]  

  • 20. Modulation of the B-A transition of DNA by potential antitumor antibiotics. Influence of the base composition of DNA.
    Fritzsche H; Rupprecht A
    J Biomol Struct Dyn; 1990 Apr; 7(5):1135-40. PubMed ID: 2361002
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.